Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency Life Science Investing
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader Life Science Investing
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update Life Science Investing
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Life Science Investing
argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026 Biotech Investing
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance Life Science Investing
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives Life Science Investing
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 Life Science Investing
Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development Life Science Investing
